Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. KZIA
KZIA logo

KZIA Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Kazia Therapeutics Ltd (KZIA) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
7.340
1 Day change
2.23%
52 Week Range
17.400
Analysis Updated At
2026/04/03
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Kazia Therapeutics Ltd (KZIA) is not a strong buy for a beginner investor with a long-term strategy at this time. The technical analysis indicates a bearish trend with no clear upward momentum, and there are no significant positive catalysts or trading signals to suggest immediate growth potential. The options data reflects low trading sentiment, and there is no recent news or financial data to support a bullish case. Given the investor's impatience and preference for long-term investments, it is better to hold off on this stock for now.

Technical Analysis

The stock is in a bearish trend with moving averages showing SMA_200 > SMA_20 > SMA_5. The MACD histogram is negative (-0.0762) and contracting, while the RSI is neutral at 48.157. Key support and resistance levels are Pivot: 7.367, R1: 7.822, S1: 6.913, R2: 8.103, S2: 6.632. No strong upward momentum is observed.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
7

Positive Catalysts

  • NULL identified. No recent news or significant trading trends from hedge funds, insiders, or Congress.

Neutral/Negative Catalysts

  • Bearish technical indicators, low trading sentiment in options data, and lack of recent positive news or financial performance data.

Financial Performance

No financial data available for the latest quarter.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes available.

Wall Street analysts forecast KZIA stock price to rise
2 Analyst Rating
Wall Street analysts forecast KZIA stock price to rise
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.180
sliders
Low
18
Averages
19
High
20
Current: 7.180
sliders
Low
18
Averages
19
High
20
H.C. Wainwright
Buy
maintain
$13 -> $18
AI Analysis
2025-12-12
Reason
H.C. Wainwright
Price Target
$13 -> $18
AI Analysis
2025-12-12
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Kazia Therapeutics to $18 from $13 and keeps a Buy rating on the shares. The company presented "encourating" results from its Phase 1 study of paxalisib for the treatment of triple-negative breast cancer, the analyst tells investors in a research note.
H.C. Wainwright
Sean Lee
Buy
upgrade
$2 -> $13
2025-07-10
Reason
H.C. Wainwright
Sean Lee
Price Target
$2 -> $13
2025-07-10
upgrade
Buy
Reason
H.C. Wainwright analyst Sean Lee raised the firm's price target on Kazia Therapeutics to $13 from $2 and keeps a Buy rating on the shares following the adjusted ratio of U.S. shares to 500:1 from 100:1.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for KZIA
Unlock Now

People Also Watch